Garo H. Armen - 10 Jul 2026 Form 4 Insider Report for AGENUS INC (AGEN)

Reporting relationship: Chairman, Chief Executive Officer and Principal Financial Officer, Director
Issuer ticker: AGEN
Reported as of: 10 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jul 2026, 15:30:03 UTC
Prior SEC filing: 30 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Melissa Orilall, as Attorney-in-Fact for Garo H. Armen

Key filing fact

Garo H. Armen filed Form 4 for AGENUS INC (AGEN) on 14 Jul 2026.

Key facts

This page summarizes Garo H. Armen's Form 4 filing for AGENUS INC (AGEN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Jul 2026, 15:30.

Change

Previous filing in this sequence was filed on 30 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000935679 Primary reporting owner

ARMEN GARO H

Relationship: Chairman, Chief Executive Officer and Principal Financial Officer, Director
Address: C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON
Signature: /s/ Melissa Orilall, as Attorney-in-Fact for Garo H. Armen
Signature date: 13 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AGEN transaction

Common Stock

Award

Transaction value
Shares: +4,852
Change %: +1.3%
Price: $3.35^*
Shares after: 371,108
Date: 10 Jul 2026
Ownership: Direct
Footnotes: F1, F2

AGEN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 31,298
Date: 10 Jul 2026
Ownership: See Footnote
Footnotes: F3

AGEN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 28,950
Date: 10 Jul 2026
Ownership: See Footnote
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 10th, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

Footnote F2

$3.35 is the closing price of our Common Stock on July 10th, 2026, the last trading day for the payroll date for the pay period ending July 10th, 2026.

Footnote F3

Shares are held in Dr. Armen's IRA accounts.

Footnote F4

Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.

SEC remarks

Chairman, Chief Executive Officer and Principal Financial Officer